The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Neurologic clinics

• Publication date

  1992-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0733-8619(18)30213-5PMID 1584177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Detection of preclinical Parkinson's disease with PET

  1991cited by this paper
• Preclinical detection of Parkinson's disease

  1991cited by this paper
• Mortality associated with early and late levodopa therapy initiation in Parkinson's disease

  1990cited by this paper
• Effect of age at onset on progression and mortality in Parkinson's disease

  1989cited by this paper
• The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

  1989cited by this paper
• Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II

  1988cited by this paper
• Rate of cell death in parkinsonism indicates active neuropathological process

  1988cited by this paper
• Does levodopa aggravate Parkinson's disease?

  1988cited by this paper
• Multi‐center study of Parkinson mortality with early versus later dopa treatment

  1987cited by this paper
• Factors that influence the occurrence of response variations in Parkinson's disease

  1987cited by this paper
• Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

  1985cited by this paper
• Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study

  1985cited by this paper
• Result of chronic levodopa therapy and its modification by bromocriptine in Parkinson's disease

  1985cited by this paper
• Age Distribution of Patients with Parkinsonism *

  1976cited by this paper
• Parkinsonism

  1967cited by this paper

• Evaluation und Wirkung von Qigong und Taiji auf den Krankheitsverlauf des M. Parkinson – ein Literaturüberblick 2006–2020

  2022cites this paper
• Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications

  2022cites this paper
• Management of advanced Parkinson’s disease in Israel: Clinicians viewpoint and action items

  2022cites this paper
• The Parkinson’s Disease-Cognitive Rating Scale: Greek Normative Data, Clinical Utility and Cultural Considerations

  2021cites this paper
• Impairment of neuronal mitochondrial function by l-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage

  2021cites this paper
• Evaluation of the psychometric properties and clinical applications of the Timed Up and Go test in Parkinson disease: a systematic review

  2020cites this paper
• Idiopathisches Parkinson-Syndrom (IPS)

  2020cites this paper
• Efecto del 2-aminoindano rígido, derivado del acenafteno, sobre la conducta estereotipada de ratas. Papel del sistema dopaminérgico cerebral

  2020cites this paper
• Adult Spinal Deformity Surgery in Patients With Movement Disorders: A Propensity-matched Analysis of Outcomes and Cost.

  2020cites this paper
• Reflektorische Atemtherapie bei Patienten mit idiopathischem Parkinson-Syndrom – Einarmige Pilotstudie

  2019cites this paper
• Dementia and Parkinson's Disease: Similar and Divergent Challenges in Providing Palliative Care

  2019cites this paper
• Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar)

  2019influential citation
• Hospitalization characteristics of Parkinson’s Disease inpatients in the United States: a nationwide analysis

  2018cites this paper
• Medical Treatment of Parkinson’s Disease

  2017cites this paper
• James Parkinson and his essay on “shaking palsy”, two hundred years later

  2017cites this paper
• Spectroscopic Analysis of Neurotransmitters: A Theoretical and Experimental Raman Study

  2017cites this paper
• Movement Disorders Curricula

  2017influential citation
• A pilot evaluation of a group exercise programme for people with Parkinson’s disease: A quantitative and qualitative approach

  2016cites this paper
• A survey of impulse control disorders in Parkinson’s disease patients in Shanghai area and literature review

  2016cites this paper
• Speech rehabilitation in Parkinson’s Disease

  2015cites this paper
• UTICAJ STRUKTURISANOG TRETMANA NA PARAMETRE HODA U REHABILITACIJI OBOLELIH OD PARKINSONOVE BOLESTI

  2015cites this paper
• Wykładniki ciśnienia tętniczego w chorobach zwyrodnieniowych układu nerwowego

  2014cites this paper
• Liquid Melevodopa Versus Standard Levodopa in Patients With Parkinson Disease and Small Intestinal Bacterial Overgrowth

  2014cites this paper
• Validation of the Korean version of the 39-Item Parkinson's Disease Questionnaire (PDQ-39).

  2014cites this paper
• Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson’s disease

  2013cites this paper
• Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson’s disease

  2013cites this paper
• Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA-lesioned rat.

  2013cites this paper
• THE STORY OF DISEASE: AN ALTERED HISTORY

  2013cites this paper
• NEUROPROTECTIVE STUDIES ON THE MPTP AND SOD1 MOUSE MODELS OF NEURODEGENERATIVE DISEASES

  2012influential citation
• Restless Legs Syndrome Predictors of caregivers ’ burden of Parkinson ’ s disease in India : experience of a tertiary care center in India

  2012cites this paper
• Health-Related Quality of Life and Healthcare Utilisation in Patients with Parkinson’s Disease

  2012cites this paper
• Rehabilitation improves dyskinesias in Parkinsonian patients: A pilot study comparing two different rehabilitative treatments

  2012cites this paper
• Predictors of caregivers’ burden of Parkinson’s disease in India: experience of a tertiary care center in India

  2012cites this paper
• Modulation of Habit Formation by Levodopa in Parkinson's Disease

  2011cites this paper
• Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson's disease.

  2011cites this paper
• Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.

  2011cites this paper
• Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection

  2011cites this paper
• Objectification of dysarthria in Parkinson's disease using Bayes theorem

  2011cites this paper
• Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions

  2011cites this paper
• [Levodopa medications in the treatment of Parkinson's disease].

  2011cites this paper
• Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists

  2011influential citation
• Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease

  2011cites this paper
• Levodopa in Parkinson's disease: from the past to the future

  2010cites this paper
• The clinical spectrum of levodopa-induced motor complications

  2010cites this paper
• Einfluss von L-Dopa und der Stimulation des Nucleus subthalamicus auf qualitative und quantitative Bewegungsparameter bei Parkinson- Patienten

  2010cites this paper
• Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

  2010cites this paper
• Rehabilitation in Parkinson's disease: Assessing the outcome using objective metabolic measurements

  2010cites this paper
• Levodopa-related wearing-off in Parkinson's disease: identification and management.

  2009cites this paper
• Levodopa-related wearing-off in Parkinson's disease: identification and management

  2009cites this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cites this paper
• Relationship between clinical phenotypes and cognitive impairment in Parkinson's disease (PD).

  2009cites this paper
• Consensus Statement of the Movement Disorder Society on Tremor

  2008cites this paper
• Levodopa unresponsive symptoms in Parkinson disease

  2008cites this paper
• The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease

  2008cites this paper
• Compulsive use of dopaminergic drugs in Parkinson's disease : a window into the role of dopamine in addiction and impulse control disorders

  2008cites this paper
• The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism.

  2008cites this paper
• Störungen von Verhalten und Impulskontrolle beim Morbus Parkinson

  2008cites this paper
• SPECT-aided diagnostics and genetic risk factors in Parkinson's disease

  2008cites this paper
• Efeito de uma Intervenção Nutricional em Doentes de Parkinson submetidos a Cirurgia de Estimulação Cerebral Profunda Effect of a Nutritional Intervention on Parkinson's Disease Patients after Deep Brain Stimulation Surgery

  2008cites this paper
• Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up

  2007cites this paper
• Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

  2007cites this paper
• Gene therapy for Parkinson's disease: early data

  2007cites this paper
• Clinical spectrum of Parkinson's disease from Pakistan.

  2006cites this paper
• The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations

  2006cites this paper
• The effects of entacapone on cardiorespiratory, autonomic, and clinical responses in L-dopa-treated patients with Parkinson's disease

  2006cites this paper
• Caregiver distress in parkinsonism.

  2006cites this paper
• The Pharmacostrategy of Treating Sleep Disorders in Parkinsonism

  2006cites this paper
• Compulsive drug use linked to sensitized ventral striatal dopamine transmission

  2006cites this paper
• Levodopa therapy from the neuroprotection viewpoint

  2005cites this paper
• Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers

  2005cites this paper
• Levodopa therapy from the neuroprotection viewpoint

  2005cites this paper
• CZECH TECHNICAL UNIVERSITY IN PRAGUE

  2005cites this paper
• Topics in Primary Care Medicine Parkinson's Disease Diagnosis and Treatment

  2005cites this paper
• Validating the Berg Balance Scale for patients with Parkinson's disease: a key to rehabilitation evaluation.

  2005cites this paper
• Pharmacokinetic–Pharmacodynamic Interaction Between BIA 3-202, a Novel COMT Inhibitor, and Levodopa/Carbidopa

  2004cites this paper
• Morbus Parkinson — Pathophysiologie, Diagnose und medikamentöse Therapie

  2004cites this paper
• Spinal Surgery in Patients with Parkinson’s Disease: Construct Failure and Progressive Deformity

  2004cites this paper
• Systematic assessment of decision models in Parkinson's disease.

  2004cites this paper
• Sensitivity to Dopamine D1/D2 Receptor Stimulation in Mice Lacking Connexin-32 or Connexin-36

  2004cites this paper
• Non-motor manifestations of \Parkinson's disease

  2004cites this paper
• Management of Parkinson Disease

  2004cites this paper
• Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?

  2003cites this paper
• Pharmacokinetic–pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide

  2003cites this paper
• Assessment of Graft Effects and Function in Cell Replacement Therapy for Parkinson's Disease

  2002cites this paper
• Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson’s disease

  2002cites this paper
• Brasofensine Treatment for Parkinson's Disease in Combination with Levodopa/Carbidopa

  2002cites this paper
• Acoustic analysis of Parkinsonian speech I: Speech characteristics and L-Dopa therapy

  2002cites this paper
• Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) or the globus pallidus interna (GPi) for treatment of advanced Parkinson's disease.

  2001cites this paper
• [Dopamine agonists situation in Parkinson disease].

  2001cites this paper
• Positronen-Emissions-Tomographie (PET)

  2001cites this paper
• An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

  2001cites this paper
• Parkin deletions in a family with adult‐onset, tremor‐dominant parkinsonism: Expanding the phenotype

  2000cites this paper
• Early Parkinson’s Disease

  2000cites this paper
• [The influence of alpha-dihydroergocryptine derivatives on psychomotor manifestations in Parkinson disease].

  2000cites this paper
• Medical and surgical treatment of Parkinson's disease. Strategies to slow symptom progression and improve quality of life.

  1999cites this paper
• Comparison of the effects of dopaminergic and serotonergic activity in the CNS on the activity of the immune system.

  1999cites this paper
• Management of Parkinson's disease

  1998cites this paper
• A frequency and correlation analysis of motor deficits in Parkinson patients.

  1998cites this paper
• Parkinson's Disease: You Make the Call

  1998cites this paper
• An algorithm (decision tree) for the management of Parkinson’s disease (2001):

  1998cites this paper